1. Home
  2. OPAD vs PHIO Comparison

OPAD vs PHIO Comparison

Compare OPAD & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OPAD

Offerpad Solutions Inc.

HOLD

Current Price

$1.35

Market Cap

10.1M

Sector

Finance

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPAD
PHIO
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.1M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
OPAD
PHIO
Price
$1.35
$0.65
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $12.25
N/A
AVG Volume (30 Days)
32.1K
★ 53.7K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.92
N/A
EPS
N/A
★ N/A
Revenue
★ $567,812,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$63.55
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.54
$0.70
52 Week High
$6.09
$1.88

Technical Indicators

Market Signals
Indicator
OPAD
PHIO
Relative Strength Index (RSI) 17.59 27.10
Support Level $0.63 N/A
Resistance Level $5.51 $1.12
Average True Range (ATR) 0.21 0.07
MACD -0.04 -0.01
Stochastic Oscillator 3.36 5.14

Price Performance

Historical Comparison
OPAD
PHIO

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: